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Human adenocarcinoma (AC) is the most frequently
diagnosed human lung cancer, and its absolute inci-
dence is increasing dramatically. Compared to human
lung AC, the A/J mouse-urethane model exhibits sim-
ilar histological appearance and molecular changes.
We examined the gene expression profiles of human
and murine lung tissues (normal or AC) and com-
pared the two species’ datasets after aligning 7500
orthologous genes. A list of 409 gene classifiers (P
value <0.0001), common to both species (joint clas-
sifiers), showed significant, positive correlation in
expression levels between the two species. A number
of previously reported expression changes were re-
capitulated in both species, such as changes in glyco-
lytic enzymes and cell-cycle proteins. Unexpectedly,
joint classifiers in angiogenesis were uniformly
down-regulated in tumor tissues. The eicosanoid
pathway enzymes prostacyclin synthase (PGIS) and
inducible prostaglandin E2 synthase (PGES) were
joint classifiers that showed opposite effects in lung
AC (PGIS down-regulated; PGES up-regulated). Fi-
nally, tissue microarrays identified the same protein
expression pattern for PGIS and PGES in 108 different
non-small cell lung cancer biopsies, and the detection
of PGIS had statistically significant prognostic value
in patient survival. Thus, the A/J mouse-urethane
model reflects significant molecular details of human
lung AC, and comparison of changes in orthologous
gene expression may provide novel insights into lung
carcinogenesis. (Am J Pathol 2005, 167:1763–1775)
In North America and developed countries, annual lung
cancer deaths account for more deaths than the com-
bined mortality due to prostate, breast, and colorectal
cancers.1 Approximately 170,000 new cases of lung can-
cer will be diagnosed this year with a 5-year survival rate
15%. Women are showing a faster increase in occur-
rence than men, presumably due to their increased to-
bacco usage after World War II.2 Better survival progno-
sis is correlated with earlier detection of the disease, with
stage IA patients showing 60% 5-year survival while
later stage detection (II to IV) 5-year survival declines to
5%.3 The poor prognosis for lung cancer patients is
generally attributed to the limited success of early detec-
tion screening methods, combined with an inability to
treat the resultant late stage, metastatic disease. Lung
cancer is divided into small cell and non-small cell histo-
logical types, with the most common form being non-
small cell lung adenocarcinoma (AC) whose incidence is
becoming more predominant.4
The earliest published description of a primary lung
tumor in mice was of a spontaneously appearing tumor in
a wild mouse in 1896.5 During the first three-quarters of
the 20th century, experimental study of murine lung tu-
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mors focused on whether their induction by chemicals
constituted an effective means of evaluating putative car-
cinogens. These early studies described primary lung
tumor development, tested the effectiveness of using
tumor antigenicity to protect recipient mice inoculated
with tumor-specific antibodies, and determined patterns
of inheritance among inbred strains of spontaneously
appearing and chemically induced tumors. An incisive
review of this system6 stimulated molecular approaches
used throughout the past 25 years to investigate progres-
sion-dependent biochemical changes that guide neo-
plastic development,7 the molecular basis of genetic sus-
ceptibility,8 detection of chemoprevention agents,9 and
application of genetically altered mice to study each of
these aspects.10
Human lung AC is often detected late in disease pro-
gression; sequential changes in the human lung leading
to the development of lung AC are infrequently observed.
The current model for the development of human lung AC
begins with atypical adenomatous hyperplasia with low-
grade histological features.11 For the A/J mouse-ure-
thane model, lung tumors proceed through hyperplastic
and adenoma stages, ultimately developing into AC.12
Urethane-induced murine AC appear to arise from alve-
olar type II epithelial cells, and a high percentage of
human ACs have characteristics suggesting some of
these tumors are also derived from alveolar type II cells.
In addition, murine and human ACs have a high fre-
quency of activating Kras mutations. Significant effort has
been put toward creating transgenic murine models of
human cancers with more than a dozen different trans-
genic mouse models of pulmonary cancer recently re-
viewed by the Mouse Models of Human Cancer Consor-
tium13 and others.14 The majority of the transgenic
models produced lung adenomas and AC histological
types through various genetic combinations, whereas
one model produced neuroendocrine tumors with small
cell lung cancer characteristics. Although transgenic
mouse studies are elegant in their approach, epidemio-
logical analyses repeatedly demonstrate the overwhelm-
ing contribution of environmental effects, such as to-
bacco usage and occupational exposures, which
together account for 90% of the lung cancer cases in
the human population. A study of the Swedish Family-
Cancer Database estimated the genetic component as
14% of the lung cancer burden in this population.15 In
addition, analysis of nonsmoking probands suggest lung
cancer incidence is best modeled through environmental
exposure rather than on a genetic basis except for some
genetic contribution in early onset disease.16
Because carcinogen exposure is responsible for the
vast majority of human lung ACs, we decided to compare
lung tissue from the A/J mouse-urethane model and hu-
man AC using microarray analysis17 to assess global
gene expression changes. This approach allowed us to
quantify the degree of molecular similarity between AC in
humans and the A/J mouse-urethane model. We hypoth-
esized that common molecular events leading to AC in
either species would result in conserved gene expression
changes between adjacent normal and tumor tissues. A
number of previously published microarray studies of
human non-small cell lung cancer (NSCLC)18–21 have
clearly shown that different histological subtypes are dis-
tinguishable and prognostic information can be obtained
by this approach. Murine lung tissue microarray studies
have been reported that emphasized discerning strain-
specific gene expression differences in normal lung.22,23
Two recent reports examined human and mouse lung
tumors in relation to murine lung development,24,25 al-
though these studies were complicated by the difficulties
of microarray cross-platform data analysis.26 In addition,
identification of orthologous genes with similar expres-
sion changes may elucidate the most conserved path-
ways underlying development of this lung cancer type.
Toward this end, a gene expression analysis of the trans-
genic murine KrasLA model27 identified a murine acti-
vated Kras expression signature.28 The murine activated
Kras expression signature was able to correctly classify
human lung AC tumor samples. Significant molecular
similarities between human disease and the A/J mouse-
urethane model would strongly support using this model
to identify early markers for disease and to test a wide
range of chemoprevention and therapeutic agents.
Materials and Methods
Mouse Lung Carcinogenesis
Male A/J mice, obtained from Jackson Laboratories (Bar
Harbor, ME), at 5 to 7 weeks of age, were allowed to
acclimate for 10 to 14 days before their use in experi-
ments. The mice were given access to Teklad-8640 stan-
dard laboratory chow (Harlan Teklad, Madison, WI) and
water ad libitum and maintained on a hardwood bedding
under a 12-hour light/dark cycle. Mice were injected once
intraperitoneally with 1 mg/g body weight urethane dis-
solved in 0.9% NaCl (saline) or saline control as de-
scribed.29 Mice were sacrificed 24 to 26 weeks or 42
weeks later by lethal injection of 100 l of 90 mg/ml
sodium pentobarbital containing 1000 U/ml heparin
(Sigma, St. Louis, MO).
Lung Tissue Preparation
Mouse
At each time point, male mice were sacrificed for either
histological examination or RNA preparation. For histol-
ogy, the lungs were perfused with saline through the right
pulmonary artery, gently inflated through a cannulated
trachea with 600 to 900 l of formalin (10% neutral buff-
ered formaldehyde solution), and incubated for 1 hour at
room temperature. Lungs were then removed from the
chest cavity and individual lobes dissected and sub-
merged in formalin overnight. Fixed lungs were trans-
ferred to 95% ethanol, embedded in paraffin, and cut in
4-m sections for histological analysis. For RNA prepa-
ration, the lung tissue was examined using a dissection
microscope immediately after the mice were sacrificed.
Tumor or normal-appearing lung parenchyma tissues
from tumor-bearing mice (adjacent tissue) were dis-
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sected and placed in 300 to 750 l of RNAlater at 4°C
(Ambion, Austin, TX) and subsequently stored at 20°C.
At the early time point, nine independent mice generated
nine adjacent and nine tumor tissue samples with an
additional three tumor samples from other mice that did
not yield sufficient quality RNA from their adjacent tissues
(total of 9 adjacent and 12 tumor samples). At 42 weeks,
eight independent mice generated 8 adjacent and 19
tumor samples from different regions of the lung.
Human
All patients participating in this study were enrolled in
a local Colorado Multiple Institutional Review Board
(COMIRB) approved protocol for use of remnant tissue
with anonymization and analysis of specimens and clin-
ical data. All but one of the patients had a history of
smoking. Patients range in age from 45 to 73 years of
age. Tumors from five males and five females were used
in the study. All specimens for microarray analysis were
obtained at surgery with nine patients undergoing lobec-
tomy and one wedge resection. Specimens were exam-
ined immediately after removal from the patient and
grossly visible solid tumor tissue was snap-frozen for
RNA extraction. The tumors were all invasive ACs, but
five specimens exhibited evidence of bronchoalveolar
differentiation at the edge of tumor nests. Most tumors
were low to intermediate grade and low stage, although
two stage III tumors were included in the analysis. The
degree of contamination of tumor cells by stromal cells
was variable and ranged from 10 to 90% but did not
affect the ability of the microarray analysis to correctly
distinguish adjacent from tumor tissue samples. Tumor
and adjacent normal tissue samples from the 10 different
AC patients were stored in liquid nitrogen until total RNA
was extracted. Approximately 100 to 300 mg of tissue
samples were cut from the frozen tissue pieces for RNA
purification.
Sample and array experiment naming convention used
the following number/letter combinations to indicate spe-
cies (Hs  human; AJ or LZ  A/J mouse), and sample
type [N or A  adjacent (normal), T  tumor]. The des-
ignation adjacent is used for normal appearing lung tis-
sue sample from either a human or a mouse with AC. This
designation recognizes that adjacent tissue from a lung
with AC may not be identical to normal tissue from an
untreated or disease-free lung. For the A/J mouse exper-
iments, the late time points at 42 weeks after urethane
injection include the number 42 in their names. The two
A/J array experiments that were consistently misclassi-
fied are labeled with a q (questionable).
Microarray Data Collection
To minimize the difficulties of cross-platform data analy-
sis,26 our study was designed around the Affymetrix
GeneChip platform for samples from either species per-
formed within one core laboratory. A/J mouse samples
included adjacent (normal histology) and tumor samples
from urethane-treated male animals. Human lung sam-
ples were from resectioned AC patients and included
both their tumor and adjacent tissue taken 1 cm from
the tumor site. Total RNA was purified from all lung tissue
samples using RNeasy kits (Qiagen, Valencia, CA). Total
RNA quality was assessed by UV spectral characteriza-
tion (A260/A280  1.9) and Agilent Bioanalyzer separa-
tion (undegraded 18S and 28S rRNA). Total RNA (2 to 5
g) was used as starting material following the Affymetrix
labeling protocol. After conversion to cRNA and fragmen-
tation, the probe was hybridized to the corresponding
species’ Affymetrix GeneChip microarray (human HG-
U95Av2 or mouse MG-U74Av2). Image data from each
microarray was scaled and normalized using Microarray
Suite 5.0 (MAS 5, Affymetrix) with the target intensity set
at 500 and normalized to 1.0. Thirty-nine human arrays
were completed from adjacent and tumor tissues derived
from 10 different patients run in duplicate. The human
arrays had an average correlation coefficient r  0.83
(SD  0.009) between duplicates with an average scal-
ing factor of 4.51 (SD  0.76). A total of 45 mouse arrays
were completed, with 44 included in this data set with an
average scaling factor of 2.52 (SD  1.06); one array
was excluded due to a significantly higher scaling
factor (8.36). All of the gene expression datasets have
been deposited at Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo/) under the following
accession numbers: human adjacent (GSM47958 to
GSM47976); human tumor (GSM36757 to GSM36776);
murine adjacent (early GSM47977 to GSM47984,
late GSM47997 to GSM48003); murine tumor (early
GSM47985 to GSM47996, late GSM48004 to
GSM48020).
Microarray Data Analysis
The MAS 5 pivot table was imported into Biometric Re-
search Branch (BRB)-ArrayTools suite [http://linus.nci.
nih.gov/BRB-ArrayTools.html; version 3.0.1a (6/03)] for
analysis. All output data were handled in Excel 2000 and
converted into Filemaker Pro 6 files. Each individual file
was linked via Affymetrix’s probe ID using Netaffx (http://
www.affymetrix.com/analysis/index.affx) orthologous gene
listing as the central database.30 Statistical analysis used
BRB-ArrayTools and JMPIN version 4 (SAS Institute,
Cary, NC). Gene ontology (GO) annotation31 was also
derived from the Netaffx website using the human probe
IDs.30 Because of redundancies present on each spe-
cies’ Affymetrix GeneChip and in the NetAffx ortholog
alignment, our analytical approach is limited to only
60% (7500/12,400 probe IDs per GeneChip) of the
complete dataset collected from each microarray exper-
iment. The BRB-ArrayTools suite makes extensive use of
parametric and permutation analyses, as well as estima-
tion of significance by false discovery rate.32 Classifiers
are cross-validated by a leave one out strategy by sev-
eral different methods.
To define a classifier, the gene expression data for a
given probe ID (data point) across all of a species’ mi-
croarrays are hypothesis tested as to whether it can
reliably distinguish between an adjacent or tumor tissues
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at a preset level of significance (parametric P value). The
null hypothesis is that the data points within a given probe
ID do not distinguish between adjacent and tumor sam-
ples. One difficulty with microarray studies is the asym-
metry in the richness of the data obtained relative to the
number of samples. In these studies, 10,800 data
points are considered per sample after orthologous align-
ment. The Bonferroni threshold is often used in this situ-
ation as a conservative approximation to provide a P
value correction at the desired level of significance. To
calculate the Bonferroni threshold, the desired level of
significance (P value) is divided by the number of data
points in the experiment. For this dataset, a desired P
value of 0.05 would need to be corrected to a required P
value of 0.000005 (0.05/10,800). Even at this conserva-
tive measure, the analysis would include 950 human
and 2000 murine probe IDs as classifiers, respectively,
with P value 0.000005. However, an unbiased measure
for determining a statistical cutoff value is using an over-
abundance plot to indicate where the cutoff can be reli-
ably placed.33 Based on this approach, the threshold
was set at a P value 0.005 to include no more than an
false discovery rate of 100 false discoveries, increasing
the probe IDs in this study to 3048 human and 4450
murine classifiers (P values 0.005). One hundred false
discoveries within the datasets would result in a potential
of 3.3% (human) and 2.2% (murine) false-positives of the
probe IDs identified. The null hypothesis would predict
only 62 probe IDs, based on all microarray probe IDs
(0.005  12,400 probe IDs on each microarray), meeting
these statistical criteria by random chance. The two spe-
cies’ individual classifier lists were then aligned using
Netaffx as an annotated source of orthologous genes.
From this alignment, 409 unique genes were identified as
joint classifiers that had P values 0.0001 for additional
study. As a test of validity of this approach, the least
statistically significant joint classifiers (P values 0.001;
n  47) were tested for their discriminating ability. The
mouse data set had two microarray experiments, one
early and one late tumor sample (LZ30 Tq and LZ73
Tq42), that were consistently misclassified, while the hu-
man data set had two tumor samples occasionally mis-
classified (Hs28 7T1 and Hs31 8T2).
Expression heat maps were generated using Cluster
and TreeView.34 The log2 expression data from the hu-
man and mouse microarrays was imported for the probe
IDs corresponding to the 409 unique genes. To keep the
output diagrams in a similar gene order, the GORDER
option was used to list the human and mouse data in the
same order. The raw data were median centered (by
genes and arrays) and clustered using the Spearman
correlation to use the high correlation by ranking.
Tissue Microarray Construction
Paraffin blocks of tumor tissue from 110 patients diag-
nosed with NSCLC (stages I to III) between 1993 through
1999 were obtained from the archives of the University of
Colorado Cancer Center (Denver, CO) and Johns Hop-
kins Medical Institutions (Baltimore, MD) according to
institutional review board-approved protocols. Patients
were followed by the tumor registries for survival time and
outcome with median follow-up of 51 months (ranging
from 18 to 100 months). The tumors were staged accord-
ing to the tumor-node-metastasis classification and his-
tologically classified according to the World Health Or-
ganization guidelines. The NSCLC tissue samples were
classified as 51 squamous, 45 AC, 7 large cell, and 7
bronchioloalveolar carcinoma histological subtypes. A
detailed listing of histological subtype, stage, and grade
is included in the on-line supplemental material at http://
ajp.amjpathol.org (Supplemental Table 1).
The tissue microarrays were assembled using a tissue-
arraying instrument (Beecher Instruments, Silver Spring,
MD), consisting of thin-walled stainless steel biopsy nee-
dles and stylets used to empty and transfer the needle
content. The assembly is held in an X-Y position guide
that is adjusted manually. A large diameter stylet (1.5
mm) was used for sampling, and nonnecrotic areas of the
blocks were routinely oversampled with three replicate
core samples of tumor (different areas) regions from each
donor block to account for tumor heterogeneity. Normal
lung and 15 other control tissues were included in each
tissue array block. Four-m sections of the resulting mi-
croarray blocks were cut with a Leitz microtome. Sections
were transferred to adhesive-coated slides using the
adhesive-coated tape-sectioning system (Instrumedics
Inc., Hackensack, NJ). Subsequently, UV light treatment
of the slides for 60 seconds polymerized the adhesive
coating into a plastic layer and sealed the sections to the
slides. Thereafter, the tape could be removed in a solvent
(Instrumedics Inc.).
Tissue Microarray Immunohistochemistry and
Analysis
The tissue sections were deparaffinized with standard
xylene and hydrated through graded alcohols into water.
Antigen retrieval was performed by heating slides in ci-
trate buffer for 20 minutes at 105°C in a Biocare Medical
decloaking chamber (Walnut Creek, CA). Peroxide block-
ing was performed with 3% hydrogen peroxide in water
for 10 minutes. Avidin and biotin blocks were done for 10
minutes each using the DAKO A/B blocking kit (DAKO,
Figure 1. A/J mouse lung tissues stained with H&E at early (26 weeks) and
late (42 weeks) time points after urethane administration shown at three
different magnifications. The early lesions are well circumscribed whereas
the late lesions show evidence of invasion and more dysplasia at higher
magnification.
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Carpinteria, CA). The sections were incubated with a
goat polyclonal anti-cyclooxygenase 2 (COX-2) antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) at a 1:400
dilution in 0.05 mol/L Tris-buffered saline with 10% bovine
serum albumin and 1% sodium azide for 1 hour at room
temperature. The secondary biotinylated rabbit anti-goat
antibody (DAKO) was applied at a 1:400 dilution with
40% normal human serum for 30 minutes at room tem-
perature. The DAKO LSAB Plus horseradish peroxidase
detection reagent was applied for 30 minutes at room
temperature followed by application of diaminobenzidine
chromogen for 5 minutes. The slides were then counter-
stained in hematoxylin and coverslipped. For prostaglan-
din E2 synthase (PGES) staining, the peroxide block was
followed by a 10-minute universal block using Power
Block (BioGenex, San Ramon, CA). The sections were
incubated with a rabbit polyclonal anti-PGES antibody
(Cayman Chemical, Ann Arbor, MI) at a 1:500 dilution
overnight at 4°C. The DAKO Envision Plus horseradish
peroxidase detection reagent was applied for 30 minutes
at room temperature followed by the application of dia-
minobenzidine chromogen for 5 minutes. For cytosolic
phospholipase A2 (cPLA2) and prostacyclin synthase
(PGIS) staining, a peroxidase anti-peroxidase system
was used and antigen retrieval was increased to 30 min-
utes in citrate buffer. For cPLA2, the peroxidase block
was followed by incubation with a goat polyclonal anti-
cPLA2 antibody (Santa Cruz Biotechnology) at 1:10 dilu-
tion overnight at 4°C. Next, a rabbit anti-goat bridging
antibody (Zymed, San Francisco, CA) was applied at a
1:200 dilution for 30 minutes at room temperature. A goat
peroxidase anti-peroxidase complex (Jackson Immu-
noresearch, West Grove, PA) was applied at a 1:400
dilution for 30 minutes at room temperature followed by
incubation with the diaminobenzidine chromogen. For
PGIS, a 10-minute universal block with Power Block fol-
lowed the peroxide block. A primary polyclonal rabbit
anti-PGIS antibody (gift from Dr. David DeWitt, Michigan
State University) was applied at a 1:25 dilution overnight
at 4°C. Slides were incubated with a goat anti-rabbit
bridging antibody (Zymed) at 1:200 dilution plus 40%
normal human serum for 30 minutes at room temperature
followed by application of a rabbit peroxidase anti-per-
oxidase complex (Zymed) at 1:250 dilution for 30 minutes
before visualization with diaminobenzidine. Either goat or
rabbit IgG (Sigma) was applied at the same concentra-
tion as the primary antibodies for negative controls. Sec-
Figure 2. A: Schematic representation of gene expression data analyses
highlighting the approach used to define the overlapping set of joint classi-
fiers between human and murine AC. In each case, the number of probe IDs
underlying each subset is indicated. Human and murine data are indicated as
Hs and Mm, respectively. B: Overabundance plot demonstrating the vast
excess of highly significant genes identified by this analysis at any P value.
The murine genes (top line), human genes (middle line), and null hypoth-
esis (bottom line) are shown as a cumulative sum versus P value. The sharp
rise for human and murine genes shown in the plot at a P value of 0.000
included probe IDs with P values 0.0001.
Figure 3. Plot of human versus murine log2 difference (tumor minus adja-
cent) intensities for the overlapping set of 409 unique genes. Different probe
IDs representing the same gene were averaged (in either species). Genes
along the diagonal represent concordant expression changes (Pearson cor-
relation r  0.61, P value 0.0001). The genes in the top left and bottom
right quadrants had discordant expression changes between human and
murine AC.
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tions were dehydrated through a series of alcohols and
xylene and covered with a glass slip.
Each core on the tissue microarray was examined by
conventional white light microscopy and the observed
staining pattern for each core graded independently by
two pathologists without knowledge of the patients’ his-
tories. A semiquantitative grading score was obtained by
multiplying the intensity of staining (0  negative, 1 
trace, 2  weak, 3  intermediate, 4  strong) by the
percentage of tumor cells stained (0 to 100%) for scores
ranging from 0 to 400. The final score is an average
among the three core samples for each patient and the
scores for both pathologists. SAS/STAT statistical pack-
age (Cary, NC) was used for the analysis of the immuno-
histochemical data. Univariate analysis was performed
using a Cox proportional hazards model to examine the
association between each of the four enzymes and sur-
vival adjusting for age, gender, and stage.35 No signifi-
cant association was found between expression level
and survival for PGES, COX-2, or cPLA2.
Results
Murine Lung Tumor Histology
As previously described,7 the A/J mouse-urethane model
provides a reproducible time course for tumor initiation,
progression, and metastasis. Typically, 30 independent
benign tumors per mouse are produced after a single
urethane injection. At the early time in these experiments
(24 to 26 weeks after urethane injection), mouse tumors
were small, self-contained nodules (adenomas) within the
lung. At the late time (42 weeks), tumors were signifi-
cantly larger, covering most of the lung volume, and
showed a strong invasive phenotype (ACs). The typical
histology observed for the A/J mouse lung AC is shown in
Figure 1. Comparisons of early and late mouse tumor
samples showed increased disorganization of tumor cells
and invasion into neighboring stroma. At higher magnifi-
cation, late mouse AC samples had more cells with en-
larged nuclei, a higher mitotic index, and frequency of
visible nucleoli. These histological findings closely paral-
lel that observed in human AC development.
Gene Expression Data Analysis
BRB-ArrayTools has several classification/prediction
modes we used for identifying probe IDs of high statisti-
cal significance common to both species.32 Each spe-
cies’ data were analyzed to determine which probe IDs
reproducibly distinguish adjacent from tumor samples
(Figure 2A). No bias was imposed for whether the genes
were up- or down-regulated in tumors relative to adjacent
tissue in either species, just that they met the statistical
criteria described in the Materials and Methods section.
One way to visualize the significance of these probe IDs
is through an overabundance plot (Figure 2B).33 The two
individual species’ classifier lists contain 3048 human
probe IDs and 4450 murine probe IDs. The null hypoth-
esis predicts only 62 probe IDs would be found at the
statistical levels used in our analysis. Sixty-two false-
positives represent only 2.0% of the probe IDs in our
classifier lists. The murine dataset consistently yielded a
larger number of classifiers than the human dataset at
any P value (Figure 2B). The increased number of murine
classifiers presumably reflects the genetic in-bred nature
of the A/J mouse as compared to humans, resulting in
smaller standard deviations in the expression levels.
NetAffx30 supplies a sequence-based orthologous
alignment of human and mouse entries cross-referenced
through the Affymetrix probe IDs. The most recent ver-
sion of NetAffx had a total of 10,790 entries without ac-
counting for redundancies within the individual species
or the alignments between them (Figure 2A). After ac-
counting for these multiple layers of redundancies, the
orthologous alignment of human and murine Affymetrix
probe IDs allows the direct comparison of 7390 unique
gene alignments between the two species (Figure 2A).
Our approach was to first identify each species’ classifi-
ers that can distinguish between adjacent and tumor
samples. Of the probe IDs that could be compared
(through the NetAffx orthologous alignment), an overlap-
ping set of joint classifiers, common to both human and
mouse, were identified. A list of 409 unique genes was
generated from the overlap of human and mouse classi-
fiers (complete listing available as an on-line spreadsheet
supplement at http://ajp.amjpathol.org).
Identification of Orthologous Classifiers
The log2 intensity difference between tumor and adjacent
samples for each of the 409 unique genes is plotted for
the human and mouse data (Figure 3). The two species’
log2 intensity differences were positively correlated
(Pearson coefficient r  0.61; P value 0.000136). Of
the 409 unique genes, 256 joint classifiers were down-
regulated (63%), 95 were up-regulated (23%), and 58
(14%) were discordant in expression (the human and
mouse log2 intensity differences were of opposite sign).
An alternative way to visualize the strong correlation
between the two species is an expression heat map
(Figure 4).34 The log2 intensity data from each species’
probe IDs displayed striking similarity in the pattern of up-
and down-regulated genes. Finally, a comparison of our
results to those from the transgenic murine KrasLA mod-
el37 indicated remarkable similarities in the unique genes
identified (42% in common) and their relative gene ex-
pression levels between AC tumors and tissue from ad-
jacent or age-matched normal littermates (Pearson coef-
Figure 4. Gene expression data for the 409 gene in the highly statistically significant subset is displayed using the Cluster and Treeview programs for the human
(A) and murine (B) datasets. The data were log-transformed, median centered by genes and arrays, followed by hierarchical clustering by Spearman rank
correlation centering. The GORDER option maintained a similar vertical ordering of the genes in both species. Green underlining indicates lung tissue adjacent
to AC, whereas red underlining indicates AC tumor samples.
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ficient r  0.82, P value 0.0001; see Supplemental
Figure S1 at http://ajp.amjpathol.org).
The 409 unique genes were used for supervised
clustering34 and representation by multidimensional
scaling (Figure 5; multidimensional scaling shown in
Supplemental Figure S2 at http://ajp.amjpathol.org) of
the human and murine datasets. The majority (95%)
of adjacent and tumor samples from either species
were correctly distinguished by both analytical ap-
proaches. The cluster tree shows that all except one
pair of human tumor duplicate samples are nearest
neighbors with high correlation values; human adja-
cent duplicate samples are nearest neighbors most of
the time, probably reflecting differing degrees of stro-
mal and/or tumor cell contamination. In the murine data
set, most nearest neighbors are from the same time
points and have extremely high correlation values. Mul-
tidimensional scaling analysis was used as a separate
measure of correlation between the human and murine
data. Multidimensional scaling was able to capture a
large amount of the variation within either species as
the first three principal components calculated by this
approach covered 65% and 68% of the total variation
in human and mouse, respectively, and were highly
statistically significant (P value 0.0 for either species;
Supplemental Figure S2 at http://ajp.amjpathol.org).
Two mouse tumor samples were consistently misclas-
sified as normal, while one human tumor sample (Hs28
7T1) was placed midway between the two groupings
(multidimensional scaling). The 409 unique genes in-
cluded in this group were each required to have a P
value 0.0001 in testing the hypothesis that individu-
ally they could distinguish between adjacent and tumor
tissues. The probability of finding 400 unique genes
together that each individually meet this level of statis-
tical significance is vanishingly small (P value 0.0),
supporting the hypothesis that there is a high degree
of molecular similarity between human and murine
lung AC.
Analysis of Extended Set of Joint Classifiers
Besides the 409 joint classifiers of high statistical con-
fidence described above, several sets of lower statis-
tically significant joint classifiers were identified to test
the potential value of all joint classifiers (Figure 6,
Supplemental Figure S3 at http://ajp.amjpathol.org).
Plots similar to Figure 3 are shown in Supplemental
Figure S4 at http://ajp.amjpathol.org, for decreasing
levels of statistical significance within the joint classi-
fier lists. As the statistical significance is relaxed from
a P value 0.0001 to include all joint classifiers (1354
probe IDs with P values 0.005), the Pearson correla-
tion decreased to r  0.51, indicating a strong rela-
tionship remained between the gene expression pat-
terns seen in both species even after including lower
ranking probe IDs. The least significant set of 47 probe
IDs having P values 0.001 (indicated in Figure 6
within the upper box) are shown in comparison to the
409 joint classifiers with P value 0.0001(contained
within the lower box). Using the 47 probe IDs in super-
vised clustering of the data resulted in the dendrogram
shown in Supplemental Figure S5 at http://ajp.amj-
pathol.org. The majority (90%) of the samples were
correctly placed on their respective branch of the den-
drograms. Further, BRB-Array Tools includes five dif-
ferent algorithms for class prediction that can also be
used in a supervised manner.32 When the datasets are
tested using only the 47 probe IDs, both human and
murine tissues were correctly identified 85% of the
time using any of the different algorithms contained in
the BRB-Microarray Tools software (data not shown). A
second approach is to use only half of the microarray
datasets for training and then test if the 47 probe IDs
are able to correctly predict the other half. In fact,
90% of the unused half of the microarray datasets
was correctly identified. Therefore, the least statisti-
cally significant joint classifiers contain sufficient infor-
mation for the correct identification of tissues in the
majority of cases. The conclusion from this analysis is
that there is significant amount of gene expression
parallelism between human and murine lung ACs, and
the genes identified through this study should lead to
testable hypotheses as to important targets for chemo-
Figure 5. Supervised clustering of human (A) and murine (B) gene expres-
sion data for the 409 genes in the highly statistically significant subset is
displayed as a dendrogram. Black triangles indicate tissue samples not
correctly identified (human 7T1 and murine LZ30Tq and LZ73 Tq42). The
three murine samples underlined in gray were not clearly associated with
either group. Green underlining indicates lung tissue adjacent to AC,
whereas red underlining indicates AC tumor samples.
Figure 6. Joint classifier subsets used in subsequent analysis are shown as
the highly statistically significant subset of 409 genes (P values 0.0001;
bottom box at left) and the least statistically significant subset of 47 genes
(P values 0.001; top box at right).
1770 Stearman et al
AJP December 2005, Vol. 167, No. 6
prevention and therapeutic development in preclinical
murine models.
Orthologous Similarities in the Hallmarks of
Cancer
Having established a strong correlation in gene expres-
sion changes in human and murine AC, we queried the
identified 409 genes for biological commonalities in well-
documented hallmarks of cancer.38 We have specifically
listed our findings in Table 1 for three of these hallmarks:
glycolysis, cell-cycle control, and angiogenesis. One of
the earliest recognized hallmark of cancer is a change in
glucose metabolism giving rise to the increased aerobic
production of lactic acid, a finding generally recognized
as the Warburg effect.39 The glycolytic pathway has be-
come a reinvigorated cancer research area through the
combination of proteomics and metabolomics.40,41 Table
1A lists the glycolytic pathway enzymes that were joint
predictors from our list of 409 genes. In all but one case,
the gene expression changes were concordant and of
the expected direction early glycolytic steps were up-
regulated including lactate dehydrogenase A, while the
terminal alcohol dehydrogenases were down-regulated.
Only phosphofructokinase (platelet) (PFKP) exhibited
discordant gene expression changes between human
and murine AC. Interestingly, the other phosphofructoki-
nase isotype (liver; PFKL), which is more highly ex-
pressed in lung (http://symatlas.gnf.org), was up-regu-
lated in both species. The human classifier had a P
value  0.00004 while the murine classifier had a P
value  0.0014, just slightly higher than our P value
cutoff, and thus not included in Table 1A. Deoxyribonu-
cleotide synthetic enzymes and many cell-cycle genes
were up-regulated in tumor compared to adjacent tissues
and the changes were concordant between the two spe-
cies (Table 1B). In particular, the late stage cyclins con-
trolling G2/M transition (cyclins A2, B1, and B2) were
Table 1. Gene Expression Changes in Three Hallmark Pathways of Cancer
Name Gene symbol Human Murine Comments
A: Glycolytic enzymes
Glucose phosphate isomerase GPI 1 1
Phosphofructokinase (platelet) PFKP 1 2 Discordant*
Aldolase A ALDOA 1 1




Enolase ENO1 1 1
Lactate dehydrogenase A LDHA 1 1 Lactate production
Alcohol dehydrogenase 1B ALDH1B 2 2
Alcohol dehydrogenase 1C ALDH1C 2 2
B: DNA biosynthesis, repair, and cell cycle
Thymidylate synthetase TYMS 1 1 DNA synthesis
Thymidine kinase 1 TK1 1 1
IMP dehydrogenase 2 IMPDH2 1 1
Spermidine synthase SRM 1 1
Growth arrest/DNA-damage inducible GADD45B 2 2 DNA repair
Growth arrest-specific 1 GAS1 2 2
Xeroderma pigmentosus group C XPC 2 2
Cell division cycle 2 (CDK1) CDC2 1 1 Multiple steps
CDC28 protein kinase regulatory subunit 1B CKS1B 1 1
CDC28 protein kinase regulatory subunit 2 CKS2 1 1
Cell division cycle 6 CDC6 1 1 G13S
Cyclin D3 CCND3 2 2
Cyclin-dependent kinase inhibitor KIP2 CDKN1C 2 2
Replication factor C 4 RFC4 1 1 S
Cell division cycle 20 CDC20 1 1 G23M
Cyclin B1 CCNB1 1 1
Cyclin B2 CCNB2 1 1
Cyclin A2 CCNA2 1 1
Chromosome condensation 1 CHC1 1 1
C: Angiogenesis-related genes
Angiopoietin 1 ANGPT1 2 2
Endothelial PAS
Domain protein 1 (HIF-2)
EPAS1 2 2
Kinase insert domain receptor (FLK1, VEGFR2) KDR 2 2
Thrombomodulin THBD 2 2
Vascular endothelial growth factor VEGF 2 2
Vascular endothelial growth factor C VEGFC 2 2
von Willebrand factor VWF 2 2
Genes identified as joint classifiers in glycolysis, cell cycle, or angiogenesis are listed with their HUGO name, and arrow indicating up-regulation
(1) or down-regulation (2) in tumor tissues relative to adjacent normal. The single asterisk indicates PFKP showed discordant gene expression
changes between human (1) and murine (2) data, although the ubiquitously expression isoform PFKL was up-regulated in both species (see text).
(The on-line web supplement at http://ajp.amjpathol.org, contains the human and mouse Affymetrix Probe IDs and log2 intensity data, as well as the
human gene symbol, chromosome location, title, and GO information for the complete set of 409 joint classifiers.)
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up-regulated. The negative regulator of G1/S transition,
the cyclin-dependent kinase inhibitor KIP2 (CDKN1C),
was down-regulated in both species and has been pre-
viously shown in murine lung cancer.42 Finally, angiogen-
esis is an important feature in cancer because it involves
many cell types and biological changes. However our
studies indicate that in general, the archetypical cancer
angiogenic markers are in fact down-regulated in lung
AC, specifically vascular endothelial growth factor (VEGF
and VEGFC), its receptor (KDR), and the hypoxia-induc-
ible transcription factor HIF-2 (Table 1C). Markers of
neovascularization (angiopoietin 1, thrombomodulin, and
von Willebrand factor) were also down-regulated in both
species.
Identification of Lung AC Biomarkers
One stated goal of using gene expression profiles is to
help identify potentially useful biomarkers for the diagno-
sis and prognosis of disease.18,19 We have listed five
genes in Table 2 that are often referenced in the recent
cancer biomarker literature as potential candidates. As
one would expect, potential biomarkers would typically
be induced in the new cell type (cancer) being diag-
nosed. Four of the potential biomarkers were up-regu-
lated in both species as well, while caveolin 1 was down-
regulated in tumor tissues. Interestingly, melanoma
antigen family members have been of high interest in
lung and other cancers,43 but to date no one has exam-
ined MAGED1 as a candidate biomarker in lung AC.
Claudin 3 has become a therapeutic target as well as a
potential biomarker in ovarian cancer,44 and our results
suggest investigating both of these possibilities in lung
AC.
Eicosanoid Pathway Gene Expression and
Patient Survival
Our laboratories have a long standing interest in the
arachidonic acid pathway, how their metabolites may
play an important role in human lung cancer, and new
avenues of therapeutic approaches.45 We are currently
testing Iloprost, a synthetic, stable PGI2 analogue, in
randomized phase II chemoprevention trials to determine
whether it can reverse the histological changes in the
bronchial epithelium of patients at high risk to develop
lung cancer.
We and others have shown that lung cancer tissues
have increased expression of PGES and decreased ex-
pression of PGIS in comparison to the adjacent normal
tissue.46 These results were mirrored in the microarray
datasets for both species, with both PGES (up-regulated)
and PGIS (down-regulated) identified as 2 of the 409 joint
classifiers. Within the context of lung cancer develop-
ment, these results, along with many others,47,48 sug-
gest that PGES and its product PGE2 have protumori-
genic effects while PGIS and its product, PGI2, are
anti-tumorigenic.
For these reasons, we investigated the expression of
PGES, COX-2, cPLA2, and PGIS by immunohistochemis-
try in 110 human NSCLC tissue samples using tissue
microarrays. Figure 7 shows staining of each of the four
factors in representative AC samples and the distribution
of scores for each of the four enzymes is shown in Sup-
plemental Figure S6 at http://ajp.amjpathol.org. PGES ex-
pression was observed in 100% of the tumors with 92%
Table 2. Genes Recently Identified as Potential Biomarkers in Human Cancers
Name Gene symbol Human Murine Reference
Caveolin 1 CAV1 2 2 55
Claudin 3 CLDN3 1 1 44**
Matrix metalloproteinase 12 MMP12 1 1 56
Melanoma antigen, family D1* MAGED1 1 1 43
Osteopontin (secreted phosphoprotein 1) SPP1 1 1 57
Gene expression changes are shown for five previously reported potential biomarkers, as designated in Table 1. The single asterisk refers to
MAGED1, which has not been reported as a biomarker but is a member of MAGE gene family, which has been reported as a biomarker for numerous
cancer types. CLDN3 has not been reported as a biomarker for lung cancer (indicated by the double asterisks) but has been reported as a biomarker
and potential therapeutic target in ovarian cancer.
Figure 7. Immunohistochemical staining of human lung AC for eicosanoid
pathway enzymes using a tissue microarray. Four enzymes [inducible pros-
taglandin E synthase (PGES), cyclooxygenase-2 (COX-2), cytosolic phospho-
lipase A2 (cPLA2), and prostacyclin synthase (PGIS)] were stained and scored
for intensity. Example of the relative staining intensity scoring system is show
at the right.
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showing strong staining (score  301 to 400). COX-2 was
expressed in 98% of tumors with 36% showing low stain-
ing (score  0 to 200), 29% showing moderate staining
(score  201 to 300), and 33% showing strong staining.
cPLA2 was expressed in all of the tumors with a majority
showing low (66%) to moderate (28%) staining. COX-2
and PGES expression was also seen in macrophages
and occasionally in normal bronchial epithelial cells. In
many cases there was a low level of cPLA2 expressed in
normal stroma and macrophages. Expression of PGIS
was primarily absent in tumor cells, occurring at very low
levels (score 17) in only 13% of the tumors.
Kaplan-Meier survival curves were generated to test
the survival benefit of positive PGIS staining versus neg-
ative PGIS staining for all NSCLC samples on the tissue
microarray (Figure 8). All of the NSCLC samples were
included in this analysis because of the limited number of
patients (14 of 108) who had positive PGIS immunostain-
ing. There was a statistically significant correlation be-
tween positive PGIS staining and increased survival (log-
rank test P values  0.047). The hazard ratio equaled
0.201, indicating an 80% reduction of mortality in patients
with positive PGIS staining. The hazard ratio was not
statistically significant (95% CI  0.027 to 1.51; P value 
0.119), presumably due to the small number of deaths
observed in the positive PGIS staining group throughout
the available follow-up time. Survival analysis was also
done categorically for PGES, COX-2, and cPLA2 by
grouping expression as low (0 to 200), intermediate (201
to 300), or high (301 to 400), and no significant associa-
tion was found between expression and survival for any
of these three proteins.
Discussion
Our results represent one of the first studies completed
using a single microarray technology within one labora-
tory comparing a murine model system to its human
disease counterpart. We have shown, by several different
statistical measures, that the gene expression changes
between tumor and adjacent normal lung tissue in human
AC are recapitulated in the A/J mouse-urethane lung AC
model with striking detail. Two hallmarks of cancer cell
biology (Warburg effect on glycolysis and cell-cycle al-
terations) were examined within the microarray datasets
and were found to be consistent with the current thinking
in what makes cancer cells different from normal cells.
The expression pattern for the cell-cycle genes would
predict that therapeutic agents active at the G2/M phase
of the cycle may offer better efficacy than at other points
in the cycle. New agents are currently being investigated
that affect this point in cell growth.49,50 A third hallmark of
cancer investigated was angiogenesis, which is associ-
ated with increased hypoxia-inducible factors’ (HIFs)
transcription targets being up-regulated. The mechanism
for the stabilization of HIFs is through the loss of von
Hippel-Lindau (VHL) protein, a classic tumor suppressor
gene, best exemplified in renal clear cell carcinoma.
Surprisingly, lung AC did not show the expected pattern
of general up-regulation of the angiogenesis genes but
showed uniformly down-regulation, particularly for the
transcription factor HIF-2. Lung tissue is uniquely situ-
ated as the internal interface to atmospheric oxygen
(21%), which may preclude the actions of the HIF path-
way in lung AC. These results would predict that thera-
peutic agents targeting angiogenesis may not prove to
be effective in treating lung AC. Clinical trials for lung
cancer of various anti-angiogenic agents are under-
way,51 although the interim results have not been
encouraging.52
In addition, we examined the arachidonic acid path-
way enzymes PGIS and PGES, which are considered
anti- and protumorigenic, respectively. The microarray
results showed that PGIS and PGES were joint classifiers
but showed opposite transcriptional effects with PGIS
down-regulated and PGES up-regulated in lung AC tu-
mor tissues compared to adjacent normal tissues. This
confirmed others46 and our results on the divergent levels
of these two enzymes seen at the protein level. We then
showed that any detectable PGIS expression in human
NSCLC lung cancer tissue microarray samples was cor-
related with increased survival of those patients. The
analysis of just these two genes (from microarray expres-
sion level to patient survival) highlights the impact the
general approach of comparing human diseases with
their murine models will have in the future.
We asked whether the orthologous gene expression
similarities could result from an explanation other than
revealing the common pathobiology in AC disease be-
tween humans and mice. Both human and murine ACs
are derived from alveolar epithelial type II cells, so one
possibility was the common cellular origin may be re-
flected in the microarray data. Surfactant protein C
(SP-C) is a highly characterized alveolar epithelial type
Figure 8. Kaplan-Meier survival curves are shown relating PGIS immunohis-
tochemical staining to patient survival time (months) from the tissue microar-
ray. Analysis for all NSCLC regardless of tumor type (total number  110
samples), was completed (PGIS-negative  94; PGIS-positive  14; 2 not
scoreable). Cox regression model was used to examine the association
between positive PGIS staining and survival after adjusting for age, gender,
and tumor stage. Survival was significantly correlated to positive PGIS stain-
ing using log-rank test (2  3.942, P value  0.047) and gave a hazard
ratio  0.20 (95% CI  0.027 to 1.51, P value  0.119). The lack of
significance in the hazard ratio is probably a function of the small number of
deaths in the positive PGIS staining group relative to the amount of follow-up
and variability in time to death.
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II-specific protein.53 Examination of the human and
mouse microarray datasets indicated similar SP-C gene
expression in tumors and adjacent normal tissues, sug-
gesting the tumors do not have a transcriptional bias due
to its type II cellular origin. In addition, Clara cell-specific
protein CC-10 (uteroglobulin) was underexpressed in tu-
mors. This suggests the strong correlation in gene ex-
pression changes between species is not a result of
common cellular origin. A second possibility is that or-
thologous gene expression similarities may be derived
from a general proliferation phenotype. This is a much
more difficult question to resolve as, in general, prolifer-
ation is part of the neoplastic phenotype.38 Although
cell-cycle and proliferation genes are highlighted in Table
1, general proliferation markers, such as proliferating cell
nuclear antigen and Ki-67, were up-regulated in tumors
compared to normal tissue but did not meet the statistical
tests that defined our joint classifiers.
In conclusion, orthologous gene expression data dem-
onstrated that many changes in human lung AC disease
are accurately replicated in the A/J-urethane murine AC
model. More than 85% of these genes had concordant
expression levels between adjacent and tumor samples
in both species. Importantly, 256 (63%) genes were
down-regulated while 95 (23%) were up-regulated in tu-
mors. The chromosomal positions for many of the human
genes match known regions of frequent loss in human
lung cancer,54 suggesting a significant role for genomic
instability in lung cancer etiology in both species. Exam-
ination of the full set of classifier genes should help
identify common affected pathways and extend the cor-
respondence between down-regulation and genomic
loss. We speculate that genomic instability and the rela-
tive scarcity of up-regulated targets may explain the lim-
ited success thus far in developing therapeutic agents for
lung AC. Orthologous gene expression analysis of AC
may lead to better therapeutic target identification. This
study represents one of the first orthologous comparisons
by gene expression analyses of a murine model and its
corresponding human disease. Our findings help vali-
date a well-defined, preclinical murine carcinogenesis
model as a platform for investigating chemoprevention
and therapeutic interventions for human lung AC. In
addition, the gene expression studies led to the investi-
gation of PGIS protein expression in a NSCLC tis-
sue microarray. We found that detection of PGIS
immunostaining in tissue samples had strong prognostic
value in predicting patient survival. The use of ortholo-
gous gene expression analysis in other disease systems
should prove useful in defining biomarkers and novel
molecular targets.
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